Eisai

News

Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.

News

The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.

News

Eisai has been given a grant from the UK that will support a £48m plan to add cold chain capabilities to its facility in Hatfield, Hertfordshire.

News

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.

News

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.